Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


BLA application for Tevimbra (tislelizumab) for first-line gastric or gastroesophageal junction cancers accepted by FDA – BeiGene

Written by | 3 Mar 2024

BeiGene, Ltd. announced that the FDA has accepted a Biologics License Application (BLA) for Tevimbra (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients… read more.

ASCO 2021: Immunotherapy shows promise in advanced esophageal squamous cell carcinoma

Written by | 21 Jun 2021

Article written by Bruce Sylvester. Researchers report that both single and dual immunotherapy improve overall survival among patients with advanced esophageal squamous cell carcinoma, particularly those positive for… read more.

FDA approves Opdivo as adjuvant treatment in oesophageal or gastroesophageal junction cancer – BMS

Written by | 23 May 2021

Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.